FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Octreotide Acetate (Sandostatin) Injection
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Novartis (New 04/28/2017)

Company Contact Information:
888-669-6682

Presentation Posting Date Related Information
1000 MCG 5 mL in 1 VIAL, MULTI-DOSE (NDC 0078-0184-25) 04/28/2017 Discontinuation of the product is not due to manufacturing, product quality, safety or efficacy concerns.
200 MCG 5 mL in 1 VIAL, MULTI-DOSE (NDC 0078-0183-25) 04/28/2017 Discontinuation of the product is not due to manufacturing, product quality, safety or efficacy concerns.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English